Navigation Links
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Date:7/23/2009

Placebo 100 mg bid ------- ---------- N 73 146 -- --- --- Diarrhea 5 7% 17 12% -------- --- --- --- --- Hypertension 3 4% 19 13% ------------ --- --- --- --- Infections 15 21% 34 23% ---------- --- --- --- --- Mean Blood Pressure (Systolic/Diastolic in mmHg) Baseline 128/78 125/77 -------- ------ ------ Month 3 126/77 129/81 ------- ------ ------ Change from Baseline to Month 3 (LOCF) -2.1/-0.5 +3.6/+3.2 -------------------- ---------- -------- N % N % --- --- --- --- # and % Had BP Meds Adjusted/Initiated 6 8% 25 17% ------------------- --- --- --- ---

Trial Design

TASKi3 was a 3 month, multi-center, randomized, double blind, placebo controlled, parallel dose clinical trial involving 219 RA patients in the U.S. who had failed to respond to at least one biologic treatment (such as TNF inhibitors). The patients were randomly assigned to two cohorts and thus received R788 orally in a 100 mg bid (twice daily) dose or placebo for a period of up to 3 months. Patients were assigned on a 2:1 basis to R788 or placebo. Throughout the clinical trial period, all of the patients continued to receive their stable dose of methotrexate.

Ef
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced the ... evaluating aldoxorubicin compared to topotecan in subjects with ... relapsed or were refractory to prior chemotherapy. Aldoxorubicin ... agent, doxorubicin. CytRx has received Orphan Drug Designation ...
(Date:9/29/2014)... et SAN DIEGO , ... Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) et ... la conclusion d,un accord de fusion définitif en ... totalité des actions ordinaires en circulation d,Ambit Biosciences ... le biais d,une offre publique d,achat qui sera ...
(Date:9/29/2014)... Calif. , Sept. 29, 2014  Bob Pack, ... driver, today called on the California Medical Association to ... Proposition 46 that the San Jose Mercury News called ... "practically everything it wants voters to believe about the ... ad attacks the Prop 46 requirement that doctors check ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... 30, 2014 World of Children Award ... of the nonprofit, Friends Without A Border (FWAB) – ... building a hospital in Cambodia that has become the ... first encountered Cambodia’s appalling lack of pediatric healthcare when ... and illnesses during a photography trip in 1993. , ...
(Date:9/30/2014)... 30, 2014 AutoTex PINK ... iconic pink ribbon in support of breast cancer awareness ... for businesses and non-profits to “go pink” -- supporting ... AutoTex PINK is a woman-owned company that is among ... are committed to partnering with their customers to raise ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Teeth replacement ... Dental Art Institute in Oxnard and Thousand Oaks, Calif., ... and tomorrow to provide training on full mouth rehabilitation. ... work, placing implants, providing cosmetic dentistry, correcting bite issues, ... said. , Dr. Jivraj, who has traveled to India ...
(Date:9/30/2014)... Minneapolis, MN (PRWEB) September 30, 2014 ... recognized leader in business technology and services was ... in First Call Effectiveness (FCE) in 2013. This ... devices properly the first time and for an ... longevity. For more than 20 years BEI Services ...
(Date:9/30/2014)... In honor of National Breast Cancer Awareness ... courageous battles, Incredible Veins, Body & Skin is offering ... Cynosure. , “For cancer patients who receive radiation ... on their skin to accurately aim the radiation on ... survivors, they decide to have their tattoo removed as ...
Breaking Medicine News(10 mins):Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 2Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 3Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:Incredible Veins, Body & Skin Takes A Stand Against Breast Cancer With PicoSure® By Cynosure 2
... spontaneous preterm birth, according to researchers at Yale School of ... at the Society for Gynecologic Investigation Conference in Reno, Nevada ... cause of illness and death in newborns. A genetic cause ... to occur within families and a high rate of recurrence, ...
... rate due to homicide, HIV disease, accidental injuries and heart ... behind the reduction in the life expectancy gap between blacks ... exist. The study is published in the March 21 issue ... generally been increasing in the United States since at least ...
... apnea having significantly higher serum levels of inflammatory markers, ... have an elevated risk of stroke, according to Japanese ... second issue for March 2007 of the American Journal ... American Thoracic Society. ,Kenji Minoguchi, M.D., Ph.D., ...
... to pay for medical treatment and prescriptions is common ... recovery//, more angina, poorer quality of life and higher ... at Yale School of Medicine. ,The study ... care services or medication were associated with worse patient ...
... is a human tumor virus which causes Kaposi’s sarcoma ... aggressive lymphomas with reported median survival time less than ... University of Helsinki have discovered that activation of the ... KSHV-infected lymphomas. ,The findings by the research ...
... blood sugar levels in women could lead// to cancer. ... of men. ,Dr Par Stattin of Umea University Medical ... over 65,000 persons. ,Writing in the journal Diabetes ... an increased risk of liver, pancreas, colon cancer, as well as ...
Cached Medicine News:Health News:Gene Variants Linked to Preterm Birth in Hispanic Women 2Health News:Black-white Life Expectancy Gap Reduces, Yet Remains Significant 2Health News:NCPAP Decreases Cerebrovascular Risk in OSA Patients 2Health News:NCPAP Decreases Cerebrovascular Risk in OSA Patients 3Health News:Due to Cost, Heart Attack Patients Often Avoid Follow-up Care and Medication 2Health News:A Novel Treatment for KSHV-infected Lymphomas 2